US Bancorp
DSGN icon

US Bancorp’s Design Therapeutics DSGN Stock Holding History

US Bancorp’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$649 Buy
+61
New +$617 ﹤0.01% 3979
2023
Q4 		– Sell
-84
Closed -$198 – 4023
2023
Q3 		$198 Sell
84
-354
-81% -$1.65K ﹤0.01% 3911
2023
Q2 		$2.76K Sell
438
-41
-9% -$251 ﹤0.01% 3622
2023
Q1 		$2.76K Buy
+479
New +$3.58K ﹤0.01% 3685

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

US Bancorp's DSGN Position: Q1 2026 in Review

US Bancorp opened a new position in Design Therapeutics (DSGN) in Q1 2026: 61 shares worth $649. The stake represents ﹤0.01% of the portfolio and ranks #3979 among its holdings. This is a return to the name: US Bancorp previously reported a position in DSGN as recently as Q3 2023.

US Bancorp first reported a position in DSGN in Q1 2023 and has held it in 4 quarters since. The position peaked at $2.76K in Q1 2023. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • US Bancorp held 61 shares of Design Therapeutics worth $649 as of Q1 2026.
  • Design Therapeutics was a new US Bancorp position in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3979 holding.
  • US Bancorp first reported a position in Design Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • US Bancorp's Design Therapeutics position peaked at $2.76K in Q1 2023.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.